Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  fludeoxyglucose F 18
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 187 for your search:
Start Over
Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice
Phase: Phase IV
Type: Diagnostic
Status: Active
Age: 60 to 80
Sponsor: Other
Protocol IDs: PROLOG, NCT00675168
CUP Project PET/CT
Phase: Phase IV
Type: Diagnostic
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: K36, NCT01469026
Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia
Phase: Phase III, Phase II
Type: Diagnostic
Status: Approved-not yet active
Age: 30 and over
Sponsor: Other
Protocol IDs: KS8-341, 2012-003604-13, NCT02010957
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
Phase: Phase III
Type: Diagnostic
Status: Active
Age: 19 to 90
Sponsor: Other
Protocol IDs: R05-0076, NCT00207298
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 17 and under
Sponsor: Other
Protocol IDs: CDR0000531687, EURONET-PHL-C1, EU-20703, EUDRACT-2006-000995-33, CCLG-HD-2007-10, NCT00433459
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CDR0000633503, GOELAMS-LH2007, GOELAMS-ID-RCB#2007-A01079-44, INCA-RECF0754, AMGEN-GOELAMS-LH2007, NCT00920153
OPTIMAL>60, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 61 to 80
Sponsor: Other
Protocol IDs: DSHNHL 2009-1, NCT01478542
Randomized Phase III of PRRT Versus Interferon
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: IJBMNCASTOR, 2012-005545-20, NCT01860742
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FIL_FOLL12, NCT02063685
To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma
Phase: Phase III
Type: Diagnostic
Status: Approved-not yet active
Age: 20 to 80
Sponsor: Other
Protocol IDs: 201111019MIB, NCT02074202
Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NARLAL 2, NCT02354274
Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 6 to 120
Sponsor: Other
Protocol IDs: HITHD-01, NCT01005043
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 30 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DEK-DKK1-P101, DKN-01, LY2812176, NCT01711671
18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Phase: Phase II, Phase I
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: VARIMG0002, NCI-2013-00535, NCT01806675
Interest of PET Imagery With 18-FDG in the Extension Assessment of the Cervical Cancer
Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: I03017, NCT00199680
Para-Aortic Lymph Nodal Staging and Evaluation of Treatment Outcome by 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Advanced Cancer Cervix
Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: TMH/205/2004/Cx_PET STUDY, NCT00193752
Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-Up of Nasopharyngeal Carcinoma.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 04-0264-C, NCT00188253
Use of Positron Emission Tomography/Computed Tomography (PET/CT) to Assess Tumor Response to Neoadjuvant Treatment for Distal Rectal Cancer
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 717/05, NCT00254683
The Utility of FDG-PET for Radiation Treatment in NSCLC
Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 20328, E-20328, NCT00385164
Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: 2006/098, NCT00503178
Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AG NUK/RT 2006-1, NCT00697333
A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer
Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BR-24334/KT-FAZ-004, NCT00771381
Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: GITIL - HD0607, NCT00795613
Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach
Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: VIS-UGI-1, NCT00800969
Start Over